Glaucoma is a group of eye conditions that can cause damage to the optic nerve and lead to vision loss. It is one of the leading causes of blindness worldwide. There are various treatment options available for glaucoma, including medications, laser therapy, and surgery. Glaucoma surgery is recommended when other treatment options have failed to control the intraocular pressure (IOP) or when the disease is advancing rapidly.

The global glaucoma surgery devices market is expected to grow at a significant rate in the coming years. The glaucoma surgery devices market was estimated at US$ 1.75 billion in 2021 and is expected to grow at a CAGR of 7.03% during 2022-2028 to reach US$ 2.81 billion in 2028.

One of the major factors driving the growth of the glaucoma surgery devices market is the increasing prevalence of glaucoma. According to the World Health Organization (WHO), glaucoma is the second leading cause of blindness globally, affecting around 70 million people. The aging population is particularly vulnerable to glaucoma, and with the world's population aging, the prevalence of glaucoma is expected to rise.

Another factor driving the market's growth is the increasing adoption of minimally invasive glaucoma surgery (MIGS) devices. MIGS devices are designed to reduce the intraocular pressure by creating a bypass for the aqueous humor, the fluid that circulates within the eye. These devices are less invasive than traditional glaucoma surgeries and have fewer complications and faster recovery times. Some of the popular MIGS devices in the market include iStent, CyPass Micro-Stent, and Hydrus Microstent.

The market is also expected to benefit from the development of new and advanced glaucoma surgery devices. For instance, in 2021, Santen Pharmaceutical Co., Ltd. received approval from the U.S. Food and Drug Administration (FDA) for its MicroShunt glaucoma drainage device. The MicroShunt is a small, flexible tube that is implanted in the eye to reduce the intraocular pressure. The device is designed to be less invasive than traditional glaucoma surgeries and has shown promising results in clinical trials.

However, the high cost of glaucoma surgery devices and the lack of reimbursement policies in some countries are expected to restrain the market's growth. The limited availability of skilled professionals who can perform glaucoma surgeries is also a significant challenge facing the market.

Request a sample here:

https://www.stratviewresearch.com/Request-Sample/3159/glaucoma-surgery-devices-market.html#form

North America is expected to dominate the glaucoma surgery devices market due to the presence of a large number of key players and a high prevalence of glaucoma in the region. Europe is also expected to witness significant growth in the market due to the increasing adoption of MIGS devices and the development of new glaucoma surgery devices.

In conclusion, the global glaucoma surgery devices market is expected to grow at a significant rate in the coming years due to the increasing prevalence of glaucoma and the adoption of MIGS devices. The development of new and advanced glaucoma surgery devices is also expected to drive the market's growth. However, the high cost of devices, the lack of reimbursement policies, and the limited availability of skilled professionals are significant challenges facing the market.